Drug Details

General Information of the Drug (ID: DR1293)
Name
Clindamycin
Synonyms
clindamycin; 18323-44-9; Chlolincocin; Dalacine; Dalacin C; Sobelin; Cleocin; UNII-3U02EL437C; 7-Chlorolincomycin; 7-Chloro-7-deoxylincomycin; Clindamycine; Antirobe; Klimicin; ClindaDerm; 3U02EL437C; U 21251; U-21251; U-21,251; Klindan 300; 7(S)-Chloro-7-deoxylincomycin; 7-Deoxy-7(S)-chlorolincomycin; (2S,4R)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; Clindamycine [French]; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Clindamicina [INN-Spanish]; 7-CDL; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; methyl 7-chloro-6,7,8-trideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-L-threo-alpha-D-galacto-octopyranoside; Clindamicina; Clindamycinum; L-threo-a-D-galacto-Octopyranoside, methyl7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; C18H33ClN2O5S; Clindamycin [USAN:INN:BAN]; SR-05000001477; HSDB 3037; Clindamycin,(S); (2S,4R)-N-[(1S,2S)-2-chloranyl-1-[(2R,3R,4S,5R,6R)-6-methylsulfanyl-3,4,5-tris(oxidanyl)oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-2-oxanyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; EINECS 242-209-1; CLDM; NSC305832; Clindamycin (USAN/INN); SCHEMBL3154; CHEMBL1753; CLINDA & IL-12; BIDD:GT0418; Clindamycin & Interleukin 12; DTXSID2022836; GTPL10607; HMS2089A05; HMS2089N16; HY-B1455; ZINC4038341; 2327AH; CC0170; AM84752; CCG-268941; CS-11147; L-threo-.alpha.-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-; CS-0013163; 58207-19-5; C06914; D00277; AB01275425-01; AB01275425_02; 323C449; A812757; A831786; SR-05000001477-1; L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-((((2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-; L-threo-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-; methyl 7-chloro-6,7,8-trideoxy-6-({[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl}amino)-1-thio-L-threo-alpha-D-galacto-octopyranoside
    Click to Show/Hide
Molecular Type
Small molecule
Disease Acne vulgaris [ICD-11: ED80] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 2.50 mg/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.75 h
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability
Bioavailability
The bioavailability of drug is 90%
Clearance
The clearance of drug is 12.3-17.4 L/h
Elimination
Approximately 10% of clindamycin bioactivity is excreted in the urine and 3.6% in the feces
Half-life
The concentration or amount of drug in body reduced by one-half in 3 hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 70.58971 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.06%
Vd
The volume of distribution (Vd) of drug is 43-74 L
Water Solubility
The ability of drug to dissolve in water is measured as 40 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C18H33ClN2O5S
PubChem CID
446598
Canonical SMILES
CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl
InChI
1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
InChIKey
KDLRVYVGXIQJDK-AWPVFWJPSA-N
CAS Number
CAS 18323-44-9
TTD Drug ID
D0R0ZL
DrugBank ID
DB01190
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Pannarin      Pannaria tavaresii     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Staphylococcus aureus Microorganism model Staphylococcus aureus
                    Experimental
                    Result(s)		 The natural compound pannarin might be a good candidate for the individualization of novel templates for the development of new antimicrobial agents or combinations of drugs for chemotherapy.
Target and Pathway
Target(s) Bacterial 50S ribosomal RNA (Bact 50S rRNA)  Molecule Info  [3]
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates. Phytomedicine. 2012 May 15;19(7):596-602.
Reference 3 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
 Download Picture         KEGG Link